


GS-SA Network for Genomic Surveillance in South Africa (NGS-SA)

SARS-CoV-2 Sequencing Update 8 July 2022


























The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 8 July 2022 at 15h14



Data license: https://www.gisaid.org/registration/terms-of-use/

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101




*76 genomes were removed as they are no longer on GISAID

Bar graphs represent genomes sequenced per epiweek, with lines representing cases by collection date (weeks 39 [2021] – 26 [2022])




Genomes and cases presented as provincial total (percentage of national total) for epiweeks 39 (2021) – 26 (2022)



^{*}This represents the cleaned, de-duplicated dataset of unique **National and Pneumonia Surveillance** sequences. This dataset will be used for all further figures.

GISAID genomes vs total cases, 2020 - 2022 (N=42 779)




All provinces, apart from GP, KZN and WC, have comparable percentages of overall cases and sequenced genomes. All provinces have contributed sequences for April and May.


June sequences are from WC, GP, FS and LP.



Number and percentage of clades by epiweek in South Africa, 2021 – 2022 (35 999*)




Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in






Detection Rates: Beta, Delta, C.1.2 and Omicron



Omicron has been dominant since November (>85% in November, >98% in December – June). BA.4 and BA.5 together dominated in April at 73%, May at 94%, and June at 96% of sequences.



South Africa, 2021-2022, n = 35 999*




^{*}Excludes sequences missing collection dates, as well as those collected January 1st and 2nd 2021 as they are part of epiweek 53 of 2020.

—— 31 - 40

—— 21 - 30

Eastern Cape Province, 2021-2022, n = 2859



— 6 - 10 **—** 11 - 20 **—** 21 - 30

— 31 - 40


— 41 - 50

Free State Province, 2021-2022, n = 1574

— 6 - 10 **—** 11 - 20 **—** 21 - 30

—— 31 - 40


— 41 - 50




Gauteng Province, 2021-2022, n = 10 121

— 31 - 40 **—** 41 - 50

— 6 - 10 **—** 11 - 20 **—** 21 - 30



KwaZulu-Natal Province, 2021-2022, n = 3883




— 6 - 10 **—** 11 - 20 **—** 21 - 30


31 - 40

— 41 - 50

Limpopo Province, 2021-2022, n = 2501




Mpumalanga Province, 2021-2022, n = 2591



— 6 - 10 **—** 11 - 20 **—** 21 - 30

— 31 - 40 **—** 41 - 50

Northern Cape Province, 2021-2022, n = 1818




— 6 - 10 **—** 11 - 20 **—** 21 - 30

—— 31 - 40

— 41 - 50


North West Province, 2021-2022, n = 2151



— 31 - 40 **—** 41 - 50

— 6 - 10 **—** 11 - 20 **—** 21 - 30

Western Cape Province, 2021-2022, n = 8496



— 31 - 40 **—** 41 - 50


— 6 - 10 **—** 11 - 20 **—** 21 - 30

Summary

- Variant of Concern Omicron in South Africa
 - Dominates 2022 sequencing data at >98% of genomes.
 - While BA.1 was the predominant lineage in January (55%), BA.2 dominated in February (86%) and March (78%).
 - Omicron lineages BA.4 and BA.5 increased in prevalence in March (16%), and together were dominant in April (73%), May (94%) and June (96%).
 - BA.2.12.1 was detected in South Africa at low prevalence in May and June (<1%)
- A low frequency of the previously circulating variant Delta was last detected in May 2022.



Omicron spike mutations compared to other VOC/VOIs



- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
 - Including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
 - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape

Only lineage-defining mutations are pictured.



















This project (RIA2020EF-3030) is part of the National Health Laboratory Service

UNIVERSITY OF MANAGEMENT OF Supported by the European Union"

ΛΛ

EDCTP











University of Stellenbosch & NHLS Tygerberg Virology



NHLS Greenpoint

水木

EDCTP

CAPETOWN HYTH

Annabel Enoch



Susan Engelbrecht **Wolfgang Preiser** Gert van Zyl Tongai Maponga **Bronwyn Kleinhans Shannon Wilson** Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen Diagnostic laboratory staff

UKZN-Inkosi Albert Luthuli Central Hospital



Dr Kerri Francois

Dr Cherise Naicker

Dr Joedene Chetty



Dr Khanvi Msomi Dr Neli Ngcaba Dr Kerusha Govender Dr Tshepiso Mosito Dr Pravi Moodlev Mr Malcolm Ellapen Dr Aabida Khan Mr Kubendran Reddy Dr Lili Gounder The COVID-19 Bench team

University of KwaZulu-Natal & Africa Health Research Institute



KRISP at UKZN: Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San**



Sequencing Core Facility

Zamantungwa Khumalo

Annie Chan

Morne du Plessis

Stanford Kwenda

Florah Mnyameni

Mushal Allam

Arshad Ismail

Phillip Senzo Mtshali

Alex Sigal Sandile Cele Willem Hanekom

University of Cape Town, NHLS & Western Cape Government

WCG-UCT

health

Mary-Anne Davies

Hannah Hussey

Andrew Boulle

Theuns Jacobs

Erna Morden

Masudah Paleker



NHLS-UCT

Carolyn Williamson Nei-yuan Hsiao Diana Hardie Kruger Marais Stephen Korsman

Zivaad Valley-Omar



UCT, IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Nokuzola Mbhele Fezokuhle Khumalo Thabang Serakge Bruna Galvão

Arghavan Alisoltani

(U. California)

Robert Wilkinson Darren Martin Nicola Mulder Wendy Burgers Ntobeko Ntusi Rageema Joseph Sean Wasserman Linda Boloko





Zoonotic arbo and respiratory virus program **Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria**



ZARV research program/UP

Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist) Carien van Niekerk



NHLS Tshwane

Prof Simnikiwe Mayaphi (HOD)

Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

National Institute for Communicable Diseases

Centre for HIV and STIs

Constantinos Kurt Wibmer

Cathrine Scheepers

Thandeka Movo

Frances Ayres

Zanele Molaudzi

Bronwen Lambson

Tandile Hermanus

Prudence Kgagudi

Mashudu Madzivhandila

Tandile Hermanus

Jinal Bhiman



Centre for Respiratory Diseases & Meningitis

Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter Sibongile Walaza Mignon du Plessis

Stefano Tempia

Mvuyo Makhasi

Cheryl Cohen

Brent Oosthuysen Penny Moore Lynn Morris

NICD Groups NICD SARS-CoV-2 Sequencing Group

NICD COVID-19 response team





Samrc






University of the **Free State**



UFS

Dominique Goedhals Armand Bester Martin Myaga Peter Mwangi **Emmanuel Ogunbayo** Milton Mogotsi Makgotso Maotoana Lutfiyya Mohamed





Felicity Burt Thokozani Mkhize Diagnostic laboratory staff







Additional support and collaborators

CAPRISA

Nigel Garret

UKZN - Big Data

Ilya Sinayskiy

José Lourenço

FioCruz, Brazil

Vagner Fonseca

Marta Giovanetti

Luiz Carlos Junior Alcantara

Francesco Pettruccione

University of Oxford

Salim Abdool Karim











NHLS Koeleka Mlisana Zinhle Makatini Eugene Elliot Florette K. Treurnicht Kathleen Subramoney Oluwakemi Laguda-Akingba **Shareef Abrahams** Greta Hoyland Gloria Selabe Elias Bereda

Hyrax Biosciences Simon Travers

Anneta Naidoo

Jeannette Wadula

Cape Town HVTN Laboratory Erica Anderson-Nissen

Ndlovu Research **Hugo Tempelman** CJ Umunnakwe

Lancet Allison J. Glass Raquel Viana **Ampath** Terry Marshall Cindy van Deventer **Eddie Silberbauer**

Pathcare Vermaak Andries Dreyer Howard Newman Riaan Writes Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

Cytespace Africa Laboratories Christa Viljoen

ARC-OVI Lia Rotherham **Africa CDC**

John Nkengasong Sofonias Tessema

Netcare:

Richard Friedland Craig Murphy Caroline Maslo Liza Sitharam

DSI **Glaudina Loots**

SA MRC Glenda Gray



















South African genomes submitted per submitting lab, 2020 - 2022 (N=42 779)





NGS-SA Labs

CERI: Centre for Epidemic Response

and Innovation

KRISP: KZN Research Innovation and

Sequencing Platform

NDLOVU: Ndlovu Research

Laboratories

NICD: National Institute for

Communicable Diseases

NHLS: National Health Laboratory

Service

SU: Stellenbosch University

UCT: University of Cape Town

UFS: University of the Free State

UP: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



Currently circulating Variants of Concern (VOC)

WHO label	Pango lineage•	GISAID clade	Nextstrain clade	Additional amino acid changes monitored°	Earliest documented samples	Date of designation
Delta	B.1.617.2	G/478K.V1	21A, 21I, 21J	+S:K417N +S:K484K	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
Omicron*	B.1.1.529	GR/484A	21K	+S:R346K	Multiple countries, Nov-2021	VUM: 24-Nov-2021 VOC: 26-Nov-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 18 March 2022

[•]Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

Only found in a subset of sequences

Previously circulating Variants of Concern

WHO label	Pango Iineage•	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY	20I (V1)	United Kingdom, Sep-2020	VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022
Beta	B.1.351	GH/501Y.V2	20H (V2)	South Africa, May-2020	VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022
Gamma	P.1	GR/501Y.V3	20J (V3)	Brazil, Nov-2020	VOC: 11-Jan-2021 Previous VOC: 09-Mar-2022

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 18 March 2022

• Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)